Nomura Asset Management Co. Ltd. Decreases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Nomura Asset Management Co. Ltd. trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 181,208 shares of the medical device company’s stock after selling 31,303 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in DexCom were worth $22,486,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Skopos Labs Inc. purchased a new stake in DexCom during the fourth quarter worth approximately $274,000. Congress Wealth Management LLC DE lifted its position in shares of DexCom by 529.5% during the 4th quarter. Congress Wealth Management LLC DE now owns 167,705 shares of the medical device company’s stock worth $20,811,000 after buying an additional 141,065 shares during the last quarter. Orion Portfolio Solutions LLC grew its position in shares of DexCom by 3.4% in the 4th quarter. Orion Portfolio Solutions LLC now owns 7,483 shares of the medical device company’s stock valued at $970,000 after buying an additional 247 shares during the last quarter. Team Hewins LLC acquired a new stake in DexCom during the 4th quarter worth $307,000. Finally, SageView Advisory Group LLC purchased a new stake in DexCom in the fourth quarter valued at $344,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.4 %

Shares of NASDAQ:DXCM traded up $1.77 during midday trading on Friday, hitting $127.37. 2,275,564 shares of the company’s stock traded hands, compared to its average volume of 2,483,182. The firm’s fifty day moving average price is $132.96 and its two-hundred day moving average price is $124.43. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a market cap of $50.65 billion, a PE ratio of 82.17, a P/E/G ratio of 3.11 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. On average, equities research analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DXCM shares. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group upped their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Citigroup increased their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $141.67.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares in the company, valued at approximately $10,747,722.01. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The disclosure for this sale can be found here. Insiders sold a total of 186,641 shares of company stock worth $25,217,707 in the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.